With an estimated annual growth of 25%, the Indian contract research and manufacturing services (CRAMS) sector is attracting global attention. Globally, drugs worth $70 billion would be going off-patent by 2011 and Indian companies providing contract manufacturing services are expected to grab approximately 30-40% of this opportunity.
It is still early if Indian companies can dominate this sector but this report interesting as it outlines the country's strengths and strategies being adopted by the sector's top players.